A multicohort phase 2 study combining pembrolizumab with low-dose cyclophosphamide in patients with advanced STS found that the 30 TLS+ patients had better outcomes than the other group (n = 41 TLS negative patients).7 Agents that promote T-cell priming and T-cell therapy are being assessed.26,27 In our immunoradiotherapy study, PD-L1 status and TLS status did not correlate with response. This evidence concerns the gene CD274 and telomere syndrome.